CynoSure president issues statement to customers over company's sale

CynoSure’s global president has assured its clinic accounts that the company’s recent sale will increase customer support. 

Erik Anderson released a statement about the aesthetic devices company’s future following news of the completion of its sale from medical technology company Hologic. 

CynoSure was acquired by an affiliate of investment funds manager Clayton, Dubilier & Rice for $205 million (approx. £157m). Hologic purchased CynoSure for $1.7 billion ($1.3bn) in 2017. 

“We are excited about the future for CynoSure with this recent announcement,” commented Anderson. “Foundationally, our business was strengthened in the last several years under Hologic, and this new acquisition by CD&R will accelerate our growth via expanded sales and marketing efforts along with further investments in innovation and new products which will support our customer partners and improve clinical outcomes for consumers.”

In the UK, CynoSure has recently been focusing efforts on promoting its latest launch, the StimSure muscle-toning device; and on a series of educational symposiums with cosmeceutical skincare brand iS Clinical.